Ipilimumab, a monoclonal antibody that blocks the negative costimulatory molecule CTLA-4 on T cells, leading to augmented T-cell activation and proliferation, improves overall survival (OS) in patients with metastatic melanoma and was approved by the regulatory agencies in the United States and several other countries for the treatment of unresectable [ Read More ]
Patrick A. Ott, MD, PhD
Member of the Melanoma Disease Center at Dana-Farber Cancer Institute and Assistant Professor of Medicine at
Harvard Medical School. He specializes in the treatment of melanoma and has a research interest in immunotherapy.
In the News
May 17, 2016